Profile data is unavailable for this security.
About the company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.
- Revenue in USD (TTM)411.01k
- Net income in USD-4.85m
- Incorporated2004
- Employees5.00
- LocationLexaria Bioscience Corp100 - 740 MCCURDY ROADKELOWNA V1X 2P7CanadaCAN
- Phone+1 (250) 765-6424
- Fax+1 (604) 685-7602
- Websitehttps://www.lexariabioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KALA BIO Inc | 0.00 | -38.96m | 29.63m | 43.00 | -- | 4.32 | -- | -- | -12.47 | -12.47 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -67.64 | -57.83 | -96.17 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.21 | 0.8367 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Opus Genetics Inc | 8.38m | -27.19m | 30.81m | 14.00 | -- | 0.7485 | -- | 3.68 | -1.09 | -1.09 | 0.3369 | 1.31 | 0.1772 | -- | 1.14 | 598,642.90 | -57.50 | -58.31 | -64.30 | -65.94 | -- | -- | -324.45 | -137.92 | -- | -- | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| ImmuCell Corp | 23.84m | -3.81m | 32.08m | 74.00 | -- | 1.20 | -- | 1.35 | -0.4856 | -0.4856 | 3.03 | 2.99 | 0.5357 | 2.35 | 11.43 | 301,746.80 | -8.56 | -5.16 | -9.39 | -5.53 | 26.71 | 40.04 | -15.99 | -12.64 | 1.44 | -6.21 | 0.2922 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Tonix Pharmaceuticals Holding Corp | 11.29m | -135.25m | 35.51m | 103.00 | -- | 0.3985 | -- | 3.14 | -52.81 | -52.81 | 0.6477 | 0.4768 | 0.0964 | 0.8291 | 4.05 | 109,621.40 | -115.46 | -59.46 | -134.34 | -65.92 | 20.74 | -- | -1,197.86 | -5,126.73 | 2.78 | -- | 0.0972 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 36.40m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Incannex Healthcare Inc | 86.00k | -23.15m | 36.87m | 9.00 | -- | 5.59 | -- | 428.76 | -1.40 | -1.40 | 0.0052 | 0.3738 | -- | -- | -- | 9,555.56 | -- | -130.12 | -- | -148.24 | -- | -- | -26,922.09 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 38.40m | 5.00 | -- | 3.44 | -- | 93.42 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 38.62m | 43.00 | -- | 4.02 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 40.47m | 100.00 | -- | -- | -- | 4.39 | -1.83 | -1.83 | 0.1979 | -0.7467 | 0.1416 | 1.67 | 4.67 | 92,100.00 | -130.68 | -55.75 | -174.03 | -78.33 | 74.08 | -- | -922.81 | -754.94 | 1.22 | -10.16 | 3.82 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Fortress Biotech Inc | 62.50m | -57.53m | 43.27m | 186.00 | -- | 2.05 | -- | 0.6924 | -3.53 | -3.53 | 3.74 | 0.767 | 0.4502 | 2.16 | 6.70 | 336,026.90 | -88.98 | -52.50 | -142.15 | -99.46 | 60.55 | 63.17 | -197.64 | -236.94 | 1.06 | -9.66 | 1.31 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| United-Guardian, Inc. | 12.31m | 3.48m | 44.61m | 25.00 | 12.80 | 3.92 | 12.44 | 3.62 | 0.7585 | 0.7585 | 2.68 | 2.48 | 0.9684 | 4.74 | 7.44 | 492,490.80 | 27.41 | 29.84 | 31.57 | 34.39 | 53.43 | 55.31 | 28.30 | 28.79 | 6.02 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| SCYNEXIS Inc | 8.57m | -36.44m | 44.78m | 29.00 | -- | 0.765 | -- | 5.23 | -0.756 | -0.756 | 0.177 | 1.54 | 0.0692 | -- | 3.61 | 295,379.30 | -29.44 | -30.02 | -35.54 | -36.35 | -71.42 | -- | -425.41 | -86.76 | -- | -- | 0.1843 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Earth Science Tech Inc | 26.89m | 2.33m | 48.58m | 32.00 | 21.08 | 15.18 | 19.60 | 1.81 | 0.0076 | 0.0076 | 0.0878 | 0.0105 | 6.65 | 23.99 | 201.60 | 840,435.90 | 57.64 | -37.98 | 79.28 | -- | 71.30 | 63.87 | 8.67 | -15.48 | 1.09 | 3.34 | 0.0241 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| BGM Group Ltd | 29.87m | -7.86m | 49.10m | 298.00 | -- | 1.12 | -- | 1.64 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
Data as of Nov 21 2024. Currency figures normalised to Lexaria Bioscience Corp's reporting currency: US Dollar USD
5.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invenomic Capital Management LPas of 30 Sep 2024 | 475.77k | 2.73% |
| Geode Capital Management LLCas of 30 Sep 2024 | 150.39k | 0.86% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 98.82k | 0.57% |
| GenTrust LLCas of 30 Sep 2024 | 60.00k | 0.34% |
| Raymond James Financial Services Advisors, Inc.as of 30 Sep 2024 | 44.90k | 0.26% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 39.30k | 0.23% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 27.45k | 0.16% |
| The Welch Group LLCas of 30 Sep 2024 | 24.00k | 0.14% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 22.98k | 0.13% |
| XTX Markets LLCas of 30 Sep 2024 | 18.63k | 0.11% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
